## Intracerebral streptozotocin model of type 3 diabetes: F disease

Journal of Alzheimer's Disease 9, 13-33

DOI: 10.3233/jad-2006-9102

**Citation Report** 

#	Article	IF	CITATIONS
1	Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: Relevance to Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 10, 89-109.	2.6	291
2	Long-term abnormalities in brain glucose/energy metabolism after inhibition of the neuronal insulin receptor: implication of tau-protein. , 2007, , 195-202.		46
3	Insulin Dysfunction Induces <i>In Vivo</i> Tau Hyperphosphorylation through Distinct Mechanisms. Journal of Neuroscience, 2007, 27, 13635-13648.	3.6	227
4	Hyperglycemia impairs glucose and insulin regulation of nitric oxide production in glucose-inhibited neurons in the ventromedial hypothalamus. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 293, R592-R600.	1.8	46
5	Nitric Oxide Synthase 3-Mediated Neurodegeneration After Intracerebral Gene Delivery. Journal of Neuropathology and Experimental Neurology, 2007, 66, 272-283.	1.7	20
6	Modification of purinergic signaling in the hippocampus of streptozotocin-induced diabetic rats. Neuroscience, 2007, 149, 382-391.	2.3	46
8	Neuronal Apoptosis in Neurodegeneration. Antioxidants and Redox Signaling, 2007, 9, 1059-1096.	5.4	196
9	Structure and Dynamics of Parallel β-Sheets, Hydrophobic Core, and Loops in Alzheimer's Aβ Fibrils. Biophysical Journal, 2007, 92, 3032-3039.	0.5	126
10	Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. , 2007, , 217-233.		182
11	Reduced insulinâ€induced phosphatidylinositolâ€3â€kinase activation in peripheral blood mononuclear leucocytes from patients with Alzheimer's disease. European Journal of Neuroscience, 2007, 26, 2469-2472.	2.6	21
12	Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. Journal of Neurochemistry, 2007, 101, 757-770.	3.9	321
13	Nerve Growth Factor Prevents the Apoptosis-associated Increase in Acetylcholinesterase Activity after Hydrogen Peroxide Treatment by Activating Akt. Acta Biochimica Et Biophysica Sinica, 2007, 39, 46-56.	2.0	24
14	Common pathological processes in Alzheimer disease and type 2 diabetes: A review. Brain Research Reviews, 2007, 56, 384-402.	9.0	322
15	Indices of Metabolic Dysfunction and Oxidative Stress. Neurochemical Research, 2007, 32, 717-722.	3.3	23
16	Molecular connexions between dementia and diabetes. Neuroscience and Biobehavioral Reviews, 2007, 31, 1046-1063.	6.1	148
17	Long-term effects of corticosterone on behavior, oxidative and energy metabolism of parietotemporal cerebral cortex and hippocampus of rats: comparison to intracerebroventricular streptozotocin. Journal of Neural Transmission, 2008, 115, 1241-1249.	2.8	46
18	Weak selfâ€association of human growth hormone investigated by nitrogenâ€15 NMR relaxation. Proteins: Structure, Function and Bioinformatics, 2008, 73, 161-172.	2.6	12
19	Insulin and Insulinâ€Like Growth Factor Resistance in Alcoholic Neurodegeneration. Alcoholism: Clinical and Experimental Research, 2008, 32, 1630-1644.	2.4	51

#	Article	IF	CITATIONS
20	Insulin, PKC signaling pathways and synaptic remodeling during memory storage and neuronal repair. European Journal of Pharmacology, 2008, 585, 76-87.	3.5	141
21	Do early-life insults contribute to the late-life development of Parkinson and Alzheimer diseases?. Metabolism: Clinical and Experimental, 2008, 57, S44-S49.	3.4	79
22	Alzheimer's Disease is Type 3 Diabetes—Evidence Reviewed. Journal of Diabetes Science and Technology, 2008, 2, 1101-1113.	2.2	853
23	Role of Insulin Metabolism Disturbances in the Development of Alzheimer Disease: Mini Review. American Journal of Alzheimer's Disease and Other Dementias, 2008, 23, 192-199.	1.9	26
24	Insulin-Like Growth Factor-II Uptake Into Choroid Plexus and Brain of Young and Old Sheep. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2008, 63, 141-148.	3.6	17
25	Therapeutic Approaches for the Treatment of Alzheimer's Disease: An Overview. , 2007, , 1-24.		5
26	Insulin Resistance Alzheimer's Disease: Pathophysiology and Treatment. Progress in Neurotherapeutics and Neuropsychopharmacology, 2008, 3, .	0.0	2
27	Limited Alzheimer-Type Neurodegeneration in Experimental Obesity and Type 2 Diabetes Mellitus. Journal of Alzheimer's Disease, 2008, 15, 29-44.	2.6	130
28	Growth Factors as Therapeutics for Diabetic Neuropathy. Current Drug Targets, 2008, 9, 47-59.	2.1	65
29	Epidemiological Trends Strongly Suggest Exposures as Etiologic Agents in the Pathogenesis of Sporadic Alzheimer's Disease, Diabetes Mellitus, and Non-Alcoholic Steatohepatitis. Journal of Alzheimer's Disease, 2009, 17, 519-529.	2.6	83
30	Mechanisms of Ceramide-Mediated Neurodegeneration. Journal of Alzheimer's Disease, 2009, 16, 705-714.	2.6	71
31	Brain Insulin-Like Growth Factor and Neurotrophin Resistance in Parkinson's Disease and Dementia with Lewy Bodies: Potential Role of Manganese Neurotoxicity. Journal of Alzheimer's Disease, 2009, 16, 585-599.	2.6	74
32	Growth Factors, AGEing, and the Diabetes Link in Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 823-831.	2.6	8
33	Hepatic Ceramide May Mediate Brain Insulin Resistance and Neurodegeneration in Type 2 Diabetes and Non-alcoholic Steatohepatitis. Journal of Alzheimer's Disease, 2009, 16, 715-729.	2.6	127
34	The Liver-Brain Axis of Alcohol-Mediated Neurodegeneration: Role of Toxic Lipids. International Journal of Environmental Research and Public Health, 2009, 6, 2055-2075.	2.6	114
35	Mechanisms of Nitrosamine-Mediated Neurodegeneration: Potential Relevance to Sporadic Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 17, 817-825.	2.6	81
36	Effects of high fat diet on Morris maze performance, oxidative stress, and inflammation in rats: Contributions of maternal diet. Neurobiology of Disease, 2009, 35, 3-13.	4.4	218
37	A metabolic and functional overview of brain aging linked to neurological disorders. Biogerontology, 2009, 10, 377-413.	3.9	76

#	Article	IF	CITATIONS
38	Curcumin ameliorates impaired insulin/IGF signalling and memory deficit in a streptozotocin-treated rat model. Age, 2009, 31, 39-49.	3.0	63
39	Nitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment. Molecular Neurodegeneration, 2009, 4, 54.	10.8	72
40	Rescue of Aβ <sub>1–42</sub> â€induced memory impairment in dayâ€old chick by facilitation of astrocytic oxidative metabolism: implications for Alzheimer's disease. Journal of Neurochemistry, 2009, 109, 230-236.	3.9	33
41	Insulin is a Two-Edged Knife on the Brain. Journal of Alzheimer's Disease, 2009, 18, 483-507.	2.6	124
42	Human cerebral neuropathology of Type 2 diabetes mellitus. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 454-469.	3.8	156
43	A study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia. Neuropharmacology, 2009, 56, 779-787.	4.1	133
44	Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutrition and Metabolism, 2009, 6, 31.	3.0	429
45	Exercise and cognitive function: a hypothesis for the association of type II diabetes mellitus and Alzheimer's disease from an evolutionary perspective. Diabetology and Metabolic Syndrome, 2009, 1, 7.	2.7	7
46	Pretreatment with Rhodiola Rosea Extract Reduces Cognitive Impairment Induced by Intracerebroventricular Streptozotocin in Rats: Implication of Anti-oxidative and Neuroprotective Effects. Biomedical and Environmental Sciences, 2009, 22, 318-326.	0.2	59
47	An Integrative View of the Role of Oxidative Stress, Mitochondria and Insulin in Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 741-761.	2.6	172
48	Ceramide-Mediated Insulin Resistance and Impairment of Cognitive-Motor Functions. Journal of Alzheimer's Disease, 2010, 21, 967-984.	2.6	86
49	A Relationship Between Alzheimer's Disease and Type 2 Diabetes Mellitus Through the Measurement of Serum Amyloid-β Autoantibodies. Journal of Alzheimer's Disease, 2010, 19, 1371-1376.	2.6	20
50	Brain glucose transporter protein 2 and sporadic Alzheimer's disease. Translational Neuroscience, 2010, 1, .	1.4	9
52	Twoâ€Ðimensional Ultraviolet (2DUV) Spectroscopic Tools for Identifying Fibrillation Propensity of Protein Residue Sequences. Angewandte Chemie - International Edition, 2010, 49, 9666-9669.	13.8	32
53	Early limited nitrosamine exposures exacerbate high fat diet-mediated type 2 diabetes and neurodegeneration. BMC Endocrine Disorders, 2010, 10, 4.	2.2	58
54	Simulation of Two Dimensional Ultraviolet (2DUV) Spectroscopy of Amyloid Fibrils. Nature Precedings, 2010, , .	0.1	0
55	Ignoring the Evidence Will Not Stop the Alzheimer's Disease/Diabetes Pandemic. Journal of Alzheimer's Disease, 2010, 21, 71-73.	2.6	0
56	Glial Vascular Degeneration in CADASIL. Journal of Alzheimer's Disease, 2010, 21, 1393-1402.	2.6	15

#	Article	IF	CITATIONS
57	Aspartyl-(asparaginyl) β-Hydroxylase, Hypoxia-Inducible Factor-1α and Notch Cross-Talk in Regulating Neuronal Motility. Oxidative Medicine and Cellular Longevity, 2010, 3, 347-356.	4.0	46
58	Rat Strain Differences in Susceptibility to Alcohol-Induced Chronic Liver Injury and Hepatic Insulin Resistance. Gastroenterology Research and Practice, 2010, 2010, 1-16.	1.5	43
60	Metabolic Changes in Rat Brain Following Intracerebroventricular Injections of Streptozotocin: A Model of Sporadic Alzheimer's Disease. Acta Neurochirurgica Supplementum, 2010, 106, 177-181.	1.0	65
61	Incretin Analogues that have been Developed to Treat Type 2 Diabetes Hold Promise as a Novel Treatment Strategy for Alzheimers Disease. Recent Patents on CNS Drug Discovery, 2010, 5, 109-117.	0.9	94
62	Role of aspartyl-(asparaginyl)-β-hydroxylase mediated notch signaling in cerebellar development and function. Behavioral and Brain Functions, 2010, 6, 68.	3.3	23
63	Organoselenium improves memory decline in mice: Involvement of acetylcholinesterase activity. Neuroscience Letters, 2010, 472, 56-60.	2.1	48
64	Protective effect of curcumin against intracerebral streptozotocin induced impairment in memory and cerebral blood flow. Life Sciences, 2010, 86, 87-94.	4.3	72
65	Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease. Biochimica Et Biophysica Acta - General Subjects, 2010, 1800, 67-79.	2.4	95
66	Protective effect of quercetin against intracerebral streptozotocin induced reduction in cerebral blood flow and impairment of memory in mice. Behavioural Brain Research, 2010, 209, 73-79.	2.2	127
67	New roles for insulin-like hormones in neuronal signalling and protection: New hopes for novel treatments of Alzheimer's disease?. Neurobiology of Aging, 2010, 31, 1495-1502.	3.1	87
68	Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Experimental Neurology, 2010, 223, 422-431.	4.1	142
69	Simulation of Two-Dimensional Ultraviolet Spectroscopy of Amyloid Fibrils. Journal of Physical Chemistry B, 2010, 114, 12150-12156.	2.6	20
70	The Role of GLP-1 in Neuronal Activity and Neurodegeneration. Vitamins and Hormones, 2010, 84, 331-354.	1.7	61
71	The Influence of Intracerebral Streptozotocin and/or Cadmium on Memory Processes in Mice Exposed to Transient Cerebral Oligemia. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2010, 73, 1159-1165.	2.3	2
72	Two-dimensional near-ultraviolet spectroscopy of aromatic residues in amyloid fibrils: a first principles study. Physical Chemistry Chemical Physics, 2011, 13, 2394-2400.	2.8	37
73	Probing Amyloid Fibril Growth by Two-Dimensional Near-Ultraviolet Spectroscopy. Journal of Physical Chemistry B, 2011, 115, 6321-6328.	2.6	12
74	Spatial Distribution of Glucose Hypometabolism Induced by Intracerebroventricular Streptozotocin in Monkeys. Journal of Alzheimer's Disease, 2011, 25, 517-523.	2.6	38
75	Dementia, Diabetes, Alzheimer's Disease, and Insulin Resistance in the Brain: Progress, Dilemmas, New Opportunities, and a Hypothesis to Tackle Intersecting Epidemics. Journal of Alzheimer's Disease, 2011, 25–29-41	2.6	52

#	Article	IF	CITATIONS
76	Insulin-resistant brain state: The culprit in sporadic Alzheimer's disease?. Ageing Research Reviews, 2011, 10, 264-273.	10.9	195
77	Improvement of brain energy metabolism and cholinergic functions contributes to the beneficial effects of silibinin against streptozotocin induced memory impairment. Behavioural Brain Research, 2011, 221, 207-215.	2.2	71
78	Sporadic dementia of Alzheimer's type induced by streptozotocin promotes anxiogenic behavior in mice. Behavioural Brain Research, 2011, 223, 1-6.	2.2	37
79	Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology, 2011, 60, 910-920.	4.1	241
80	The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiology of Learning and Memory, 2011, 96, 529-543.	1.9	386
81	Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function. Molecular BioSystems, 2011, 7, 1822.	2.9	129
82	Protective Roles of the Incretin Hormones Glucagon-Like Peptide-1 and Glucose-Dependent Insolinotropic Polypeptide Hormones in Neurodegeneration. , 0, , .		0
83	The ε3 and ε4 Alleles of Human APOE Differentially Affect Tau Phosphorylation in Hyperinsulinemic and Pioglitazone Treated Mice. PLoS ONE, 2011, 6, e16991.	2.5	34
84	CSF Aβ1-42 Levels and Glucose Metabolism in Alzheimer's Disease>. Journal of Alzheimer's Disease, 2011, 27, 845-851.	2.6	20
85	Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer's disease: a long-term follow up study. Journal of Neural Transmission, 2011, 118, 765-772.	2.8	117
86	si-RNA inhibition of brain insulin or insulin-like growth factor receptors causes developmental cerebellar abnormalities: relevance to fetal alcohol spectrum disorder. Molecular Brain, 2011, 4, 13.	2.6	47
87	Carbohydrates for improving the cognitive performance of independent-living older adults with normal cognition or mild cognitive impairment. The Cochrane Library, 2011, , CD007220.	2.8	18
88	Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities. Experimental Diabetes Research, 2011, 2011, 1-6.	3.8	29
89	Alzheimer's Disease and Environmental Exposure to Lead: The Epidemiologic Evidence and Potential Role of Epigenetics. Current Alzheimer Research, 2012, 9, 563-573.	1.4	163
90	The anti-neurodegenerative agent clioquinol regulates the transcription factor FOXO1a. Biochemical Journal, 2012, 443, 57-64.	3.7	9
91	Tumor Necrosis Factor-Induced Cerebral Insulin Resistance in Alzheimer's Disease Links Numerous Treatment Rationales. Pharmacological Reviews, 2012, 64, 1004-1026.	16.0	65
92	Dysfunctional Pro-Ceramide, ER Stress, and Insulin/IGF Signaling Networks with Progression of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 30, S217-S229.	2.6	68
93	PTEN, a widely known negative regulator of insulin/PI3K signaling, positively regulates neuronal insulin resistance. Molecular Biology of the Cell, 2012, 23, 3882-3898.	2.1	92

#	Article	IF	CITATIONS
94	Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease. Current Alzheimer Research, 2012, 9, 35-66.	1.4	373
95	Triangulated Mal-Signaling in Alzheimer's Disease: Roles of Neurotoxic Ceramides, ER Stress, and Insulin Resistance Reviewed. Journal of Alzheimer's Disease, 2012, 30, S231-S249.	2.6	78
98	Down-Regulation of Amyloid-β Through AMPK Activation by Inhibitors of GSK-3β in SH-SY5Y and SH-SY5Y-AβPP695 Cells. Journal of Alzheimer's Disease, 2012, 29, 89-98.	2.6	27
99	Role of stereotaxically injected IgG from db/db mice in the phosphorylation of the microtubule-associated protein tau in hippocampus. Brain Research, 2012, 1486, 14-26.	2.2	5
100	Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4. Age, 2012, 34, 1211-1224.	3.0	106
101	Amelioration of intracerebroventricular streptozotocin induced cognitive impairment by Evolvulus alsinoides in rats: In vitro and in vivo evidence. Neurochemistry International, 2012, 61, 1052-1064.	3.8	25
102	Naringenin ameliorates Alzheimer's disease (AD)-type neurodegeneration with cognitive impairment (AD-TNDCI) caused by the intracerebroventricular-streptozotocin in rat model. Neurochemistry International, 2012, 61, 1081-1093.	3.8	137
103	Frequency Distribution of the Amide-I Vibration Sorted by Residues in Amyloid Fibrils Revealed by 2D-IR Measurements and Simulations. Journal of Physical Chemistry B, 2012, 116, 3322-3330.	2.6	31
104	Central insulin resistance and synaptic dysfunction in intracerebroventricular-streptozotocin injected rodents. Neurobiology of Aging, 2012, 33, 430.e5-430.e18.	3.1	68
105	Insulin resistance in the nervous system. Trends in Endocrinology and Metabolism, 2012, 23, 133-141.	7.1	235
106	Insulin in Central Nervous System: More than Just a Peripheral Hormone. Journal of Aging Research, 2012, 2012, 1-21.	0.9	227
107	Altered gene expression profiles in the hippocampus and prefrontal cortex of type 2 diabetic rats. BMC Genomics, 2012, 13, 81.	2.8	48
108	Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neuroscience, 2012, 13, 33.	1.9	372
109	Contributions of Brain Insulin Resistance and Deficiency in Amyloid-Related Neurodegeneration in Alzheimer's Disease. Drugs, 2012, 72, 49-66.	10.9	202
110	Early and late neurodegeneration and memory disruption after intracerebroventricular streptozotocin. Physiology and Behavior, 2012, 107, 401-413.	2.1	63
111	Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection. CNS Drugs, 2012, 26, 871-882.	5.9	156
112	Quintessential Risk Factors: Their Role in Promoting Cognitive Dysfunction and Alzheimer's Disease. Neurochemical Research, 2012, 37, 2627-2658.	3.3	62
113	In Vivo Cross-sectional Characterization of Cerebral Alterations Induced by Intracerebroventricular Administration of Streptozotocin. PLoS ONE, 2012, 7, e46196.	2.5	83

#	Article	IF	CITATIONS
114	Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. Frontiers in Bioscience - Elite, 2012, E4, 1582.	1.8	39
115	Dementia – A Complete Literature Review on Various Mechanisms Involves in Pathogenesis and an Intracerebroventricular Streptozotocin Induced Alzheimer's Disease. , 2012, , .		6
116	Amyloid-β Oligomers Induce Differential Gene Expression in Adult Human Brain Slices. Journal of Biological Chemistry, 2012, 287, 7436-7445.	3.4	80
117	Initial Stages of the Insulin Signaling System in the Brain of Rats with Experimental Diabetes Mellitus. Bulletin of Experimental Biology and Medicine, 2012, 153, 25-28.	0.8	1
118	Ceramide profiles in the brain of rats with diabetes induced by streptozotocin. FEBS Journal, 2012, 279, 1943-1952.	4.7	24
119	Alcohol, insulin resistance and the liver–brain axis. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 33-41.	2.8	71
120	Neuroprotective effects of D-Ala2GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model. Alzheimer's Research and Therapy, 2013, 5, 20.	6.2	59
121	Clitoria ternatea ameliorated the intracerebroventricularly injected streptozotocin induced cognitive impairment in rats: behavioral and biochemical evidence. Psychopharmacology, 2013, 230, 589-605.	3.1	17
123	Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: Implications for diagnostic and therapeutic strategies. Progress in Neurobiology, 2013, 108, 21-43.	5.7	499
124	Hippocampal calcium dysregulation at the nexus of diabetes and brain aging. European Journal of Pharmacology, 2013, 719, 34-43.	3.5	31
125	Hyperphosphorylation of Tau Protein in Hippocampus of Central Insulin-Resistant Rats is Associated with Cognitive Impairment. Cellular Physiology and Biochemistry, 2013, 32, 1417-1425.	1.6	39
126	Sex and ApoE Genotype Differences in Treatment Response to Two Doses of Intranasal Insulin in Adults with Mild Cognitive Impairment or Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 789-797.	2.6	186
127	The Importance of Olfactory and Motor Endpoints for Zebrafish Models of Neurodegenerative Disease. , 2013, , 651-678.		0
128	Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease. Journal of Pharmacy and Pharmacology, 2013, 65, 1773-1784.	2.4	123
129	O-linked β-N-acetylglucosaminidase inhibitor attenuates β-amyloid plaque and rescues memory impairment. Neurobiology of Aging, 2013, 34, 275-285.	3.1	98
130	What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research. Journal of Neural Transmission, 2013, 120, 233-252.	2.8	220
131	Sweet memories: 20 years of progress in research on cognitive functioning in diabetes. European Journal of Pharmacology, 2013, 719, 153-160.	3.5	18
132	Crosstalk between diabetes and brain: Glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 527-541.	3.8	113

#	Article	IF	CITATIONS
133	Food for thought: The role of appetitive peptides in age-related cognitive decline. Ageing Research Reviews, 2013, 12, 764-776.	10.9	55
134	Brain Insulin Dysregulation: Implication for Neurological and Neuropsychiatric Disorders. Molecular Neurobiology, 2013, 47, 1045-1065.	4.0	93
135	Association between the characteristics of metabolic syndrome and Alzheimer's disease. Metabolic Brain Disease, 2013, 28, 597-604.	2.9	14
136	Molecular Dynamics Simulation and Computational Two-Dimensional Infrared Spectroscopic Study of Model Amyloid β-Peptide Oligomers. Journal of Physical Chemistry A, 2013, 117, 6373-6379.	2.5	10
137	Taurine ameliorates neurobehavioral, neurochemical and immunohistochemical changes in sporadic dementia of Alzheimer's type (SDAT) caused by intracerebroventricular streptozotocin in rats. Neurological Sciences, 2013, 34, 2181-2192.	1.9	40
138	A Non-transgenic Mouse Model (icv-STZ Mouse) of Alzheimer's Disease: Similarities to and Differences from the Transgenic Model (3xTg-AD Mouse). Molecular Neurobiology, 2013, 47, 711-725.	4.0	226
139	The Role of HSP70 in the Protection of: (A) The Brain in Alzheimer's Disease and (B) The Heart in Cardiac Surgery. SpringerBriefs in Biochemistry and Molecular Biology, 2013, , 113-139.	0.3	2
140	Therapeutic effect of organoselenium dietary supplementation in a sporadic dementia of Alzheimer's type model in rats. Journal of Nutritional Biochemistry, 2013, 24, 311-317.	4.2	48
141	All-trans retinoic acid rescues memory deficits and neuropathological changes in mouse model of streptozotocin-induced dementia of Alzheimer's type. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 40, 38-46.	4.8	54
142	Ameliorative effect of Noni fruit extract on streptozotocin-induced memory impairment in mice. Behavioural Pharmacology, 2013, 24, 307-319.	1.7	31
143	Cinnamon Counteracts the Negative Effects of a High Fat/High Fructose Diet on Behavior, Brain Insulin Signaling and Alzheimer-Associated Changes. PLoS ONE, 2013, 8, e83243.	2.5	53
145	Insulin/IGF Signaling-Related Gene Expression in the Brain of a Sporadic Alzheimer's Disease Monkey Model Induced by Intracerebroventricular Injection of Streptozotocin. Journal of Alzheimer's Disease, 2013, 38, 251-267.	2.6	42
146	Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art. Expert Opinion on Drug Delivery, 2013, 10, 1699-1709.	5.0	68
147	D-Ala2GIP Facilitated Synaptic Plasticity and Reduces Plaque Load in Aged Wild Type Mice and in an Alzheimer's Disease Mouse Model. Journal of Alzheimer's Disease, 2013, 35, 267-283.	2.6	51
148	CSF and Brain Indices of Insulin Resistance, Oxidative Stress and Neuro-Inflammation in Early versus Late Alzheimer's Disease. , 2013, 03, 128.		39
149	Selection of Appropriate Reference Genes for RT-qPCR Analysis in a Streptozotocin-Induced Alzheimer's Disease Model of Cynomolgus Monkeys (Macaca fascicularis). PLoS ONE, 2013, 8, e56034.	2.5	13
150	Modeling Alzheimer's disease: from past to future. Frontiers in Pharmacology, 2013, 4, 77.	3.5	40
151	Diverse Molecular Targets for Therapeutic Strategies in Alzheimer's Disease. Journal of Korean Medical Science, 2014, 29, 893.	2.5	21

		CITATION RE	PORT	
#	Article		IF	CITATIONS
152	Insulin dysfunction and Tau pathology. Frontiers in Cellular Neuroscience, 2014, 8, 22.		3.7	95
153	Agmatine Improves Cognitive Dysfunction and Prevents Cell Death in a Streptozotocin Alzheimer Rat Model. Yonsei Medical Journal, 2014, 55, 689.	Induced	2.2	72
154	The effect of treadmill exercise on inflammatory responses in rat model of streptozotoo experimental dementia of Alzheimer's type. Journal of Exercise Nutrition & Biochem 225-233.	:in-induced istry, 2014, 18,	1.3	21
155	Impaired Insulin Signaling and Mechanisms of Memory Loss. Progress in Molecular Biolo Translational Science, 2014, 121, 413-449.	bgy and	1.7	42
156	Current Challenges to Overcome in the Management of Type 2 Diabetes Mellitus and A Neurological Disorders. CNS and Neurological Disorders - Drug Targets, 2014, 13, 1440	ssociated +1457.	1.4	10
157	Glaucoma – Diabetes of the brain: A radical hypothesis about its nature and pathoge Hypotheses, 2014, 82, 535-546.	nesis. Medical	1.5	16
158	Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats trea intracerebroventricularly with streptozotocin. Neuropharmacology, 2014, 77, 68-80.	ced	4.1	67
159	Anthocyanins restore behavioral and biochemical changes caused by streptozotocin-ind dementia of Alzheimer's type. Life Sciences, 2014, 96, 7-17.	luced sporadic	4.3	96
160	Dipeptidyl peptidase-4 inhibition by Pterocarpus marsupium and Eugenia jambolana am streptozotocin induced Alzheimer's disease. Behavioural Brain Research, 2014, 267, 55	eliorates -65.	2.2	45
161	Effect of naringenin on brain insulin signaling and cognitive functions in ICV-STZ induce model of rats. Neurological Sciences, 2014, 35, 741-751.	d dementia	1.9	66
162	Brain metabolic dysfunction at the core of Alzheimer's disease. Biochemical Pharmacolo 548-559.	ogy, 2014, 88,	4.4	374
163	Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseas Endocrinology, 2014, 221, T31-T41.	es. Journal of	2.6	224
164	Oral Inflammation, Tooth Loss, Risk Factors, and Association with Progression of Alzhei Journal of Alzheimer's Disease, 2014, 42, 723-737.	mer's Disease.	2.6	76
165	Insulin resistance in Alzheimer's disease. Neurobiology of Disease, 2014, 72, 92-103.		4.4	92
166	Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's Parkinson's diseases. Biochemical Society Transactions, 2014, 42, 593-599.	s and	3.4	91
167	Relationships Between Diabetes and Cognitive Impairment. Endocrinology and Metabo North America, 2014, 43, 245-267.	lism Clinics of	3.2	63
168	Type 3 diabetes is sporadic Alzheimer× <sup>3</sup> s disease: Mini-review. European Neuropsychop 24, 1954-1960.	harmacology, 2014,	0.7	237
169	Efficacy of bosentan, a dual ETA and ETB endothelin receptor antagonist, in experiment induced vascular endothelial dysfunction and associated dementia in rats. Pharmacolog Biochemistry and Behavior, 2014, 124, 27-35.	al diabetes Sy	2.9	21

		CITATION REPORT	
#	Article	IF	Citations
170	Animal models of dementia and cognitive dysfunction. Life Sciences, 2014, 109, 73-86.	4.3	73
171	Characterization of Cerebral Damage in a Monkey Model of Alzheimer's Disease Induced by Intracerebroventricular Injection of Streptozotocin. Journal of Alzheimer's Disease, 2015, 46, 989	9-1005. 2.6	40
172	Tobacco Smoke Exposure Impairs Brain Insulin/IGF Signaling: Potential Co-Factor Role in Neurodegeneration. Journal of Alzheimer's Disease, 2016, 50, 373-386.	2.6	25
173	Tobacco Smoke-Induced Brain White Matter Myelin Dysfunction: Potential Co-Factor Role of Sm in Neurodegeneration. Journal of Alzheimer's Disease, 2015, 50, 133-148.	oking 2.6	34
174	Aberrant insulin signaling in Alzheimer's disease: current knowledge. Frontiers in Neuroscience, 2 9, 204.	2015, 2.8	229
175	Neuroinflammation is not a Prerequisite for Diabetes-induced Tau Phosphorylation. Frontiers in Neuroscience, 2015, 9, 432.	2.8	9
176	Diabetes and Alzheimer Disease, Two Overlapping Pathologies with the Same Background: Oxida Stress. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-14.	ative 4.0	91
177	Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Experimental and Molecular Medicine, 2015, 47, e149-e149.	7.7	225
178	Rodent models of neuroinflammation for Alzheimer's disease. Journal of Neuroinflammation, 74.	2015, 12, 7.2	191
179	In vitro streptozotocin model for modeling Alzheimer-like changes: effect on amyloid precursor protein secretases and glycogen synthase kinase-3. Journal of Neural Transmission, 2015, 122, 5	51-557. <sup>2.8</sup>	27
180	Nine-month follow-up of the insulin receptor signalling cascade in the brain of streptozotocin rat model of sporadic Alzheimer's disease. Journal of Neural Transmission, 2015, 122, 565-576.	2.8	41
181	Multi-target iron-chelators improve memory loss in a rat model of sporadic Alzheimer's disease. L Sciences, 2015, 136, 108-119.	ife 4.3	46
182	How to Stabilize Both the Proteins and the Membranes: Diverse Effects of sHsps in Neuroprotect Heat Shock Proteins, 2015, , 527-562.	tion. 0.2	4
183	Quantitative Expression Analysis of APP Pathway and Tau Phosphorylation-Related Genes in the STZ-Induced Non-Human Primate Model of Sporadic Alzheimer's Disease. International Journ Molecular Sciences, 2015, 16, 2386-2402.	CV al of 4.1	33
184	Caffeic acid improves memory impairment and brain glucose metabolism via ameliorating cerebr insulin and leptin signaling pathways in high-fat diet-induced hyperinsulinemic rats. Food Researd International, 2015, 77, 24-33.	al ch 6.2	18
185	Dose effect of gestational ethanol exposure on placentation and fetal growth. Placenta, 2015, 3 523-530.	6, 1.5	44
186	Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer's disease. Journal of Neural Transmission, 202577-592.	15, 122, 2.8	101
187	Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats. European Journal of Pharmacology, 2015, 765, 482-487.	3.5	76

#	Article	IF	CITATIONS
188	Differential Contributions of Alcohol and the Nicotine-Derived Nitrosamine Ketone (NNK) to Insulin and Insulin-Like Growth Factor Resistance in the Adolescent Rat Brain. Alcohol and Alcoholism, 2015, 50, 670-679.	1.6	22
189	Linking insulin with Alzheimer's disease: emergence as type III diabetes. Neurological Sciences, 2015, 36, 1763-1769.	1.9	49
190	Insulin Resistance Prevents AMPK-induced Tau Dephosphorylation through Akt-mediated Increase in AMPKSer-485 Phosphorylation. Journal of Biological Chemistry, 2015, 290, 19146-19157.	3.4	45
191	Characterization of cognitive deficits in spontaneously hypertensive rats, accompanied by brain insulin receptor dysfunction. Journal of Molecular Psychiatry, 2015, 3, 6.	2.0	23
192	Puerarin attenuates learning and memory impairments and inhibits oxidative stress in STZ-induced SAD mice. NeuroToxicology, 2015, 51, 166-171.	3.0	53
193	Cognitive effects of vanillic acid against streptozotocin-induced neurodegeneration in mice. Pharmaceutical Biology, 2015, 53, 630-636.	2.9	94
194	Cellular and metabolic alterations in the hippocampus caused by insulin signalling dysfunction and its association with cognitive impairment during aging and Alzheimer's disease: studies in animal models. Diabetes/Metabolism Research and Reviews, 2015, 31, 1-13.	4.0	61
195	Central activation of PPAR-gamma ameliorates diabetes induced cognitive dysfunction and improves BDNF expression. Neurobiology of Aging, 2015, 36, 1451-1461.	3.1	84
196	Neuroprotective effect of ebselen against intracerebroventricular streptozotocin-induced neuronal apoptosis and oxidative stress in rats. Toxicology and Industrial Health, 2016, 32, 730-740.	1.4	21
197	Tobacco Nitrosamine Exposures Contribute to Fetal Alcohol Spectrum Disorder Associated Cerebellar Dysgenesis. International Journal of Biology, 2016, 8, 10.	0.2	0
198	Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Dise ase Pathologies. , 2016, 6, .		29
199	Alcoholic Beverage and Insulin Resistance–Mediated Degenerative Diseases of Liver and Brain. , 2016, , 237-251.		0
200	Glucose Metabolism, Insulin, and Aging. , 2016, , 393-409.		4
201	Neurodegenerative Diseases: Might Citrus Flavonoids Play a Protective Role?. Molecules, 2016, 21, 1312.	3.8	97
202	Meta-Analysis of Serum Insulin-Like Growth Factor 1 in Alzheimer's Disease. PLoS ONE, 2016, 11, e0155733.	2.5	42
203	T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 51, 123-138.	2.6	38
204	Improved Brain Insulin/IGF Signaling andÂReduced Neuroinflammation withÂT3D-959 in an Experimental ModelÂofÂSporadic Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 55, 849-864.	2.6	59
205	Glucose Transporters in Brain: In Health and in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 55, 1307-1320.	2.6	160

#	Article	IF	CITATIONS
207	Alzheimer's disease: Is this a brain specific diabetic condition?. Physiology and Behavior, 2016, 164, 259-267.	2.1	38
208	Transcriptional control of physiological and pathological processes by the nuclear receptor PPARβ/Î′. Progress in Lipid Research, 2016, 64, 98-122.	11.6	58
209	The Differential Effects of Alcohol and Nicotine-Specific Nitrosamine Ketone on White Matter Ultrastructure. Alcohol and Alcoholism, 2017, 52, 165-171.	1.6	12
210	Diphenyl diselenide supplementation in infected mice by Toxoplasma gondii: Protective effect on behavior, neuromodulation and oxidative stress caused by disease. Experimental Parasitology, 2016, 169, 51-58.	1.2	24
211	Hydralazine inhibits amyloid beta (Aβ) aggregation and glycation and ameliorates Aβ <sub>1–42</sub> induced neurotoxicity. RSC Advances, 2016, 6, 108768-108776.	3.6	6
213	Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide analogues as novel treatments for Alzheimer's and Parkinson's disease. Cardiovascular Endocrinology, 2016, 5, 93-98.	0.8	24
214	Insulin potentiates the therapeutic effect of memantine against central STZ-induced spatial learning and memory deficit. Behavioural Brain Research, 2016, 311, 247-254.	2.2	10
215	Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. Reviews in the Neurosciences, 2016, 27, 689-711.	2.9	27
216	Downstream modulation of extrinsic apoptotic pathway in streptozotocin-induced Alzheimer's dementia in rats: Erythropoietin versus curcumin. European Journal of Pharmacology, 2016, 770, 52-60.	3.5	56
217	The rise and fall of insulin signaling in Alzheimer's disease. Metabolic Brain Disease, 2016, 31, 497-515.	2.9	42
218	Puerarin ameliorates cognitive deficits in streptozotocin-induced diabetic rats. Metabolic Brain Disease, 2016, 31, 417-423.	2.9	39
219	Effect of acute lipopolysaccharide-induced inflammation in intracerebroventricular-streptozotocin injected rats. Neuropharmacology, 2016, 101, 110-122.	4.1	10
220	Streptozotocin Intracerebroventricular-Induced Neurotoxicity and Brain Insulin Resistance: a Therapeutic Intervention for Treatment of Sporadic Alzheimer's Disease (sAD)-Like Pathology. Molecular Neurobiology, 2016, 53, 4548-4562.	4.0	104
221	Intracerebroventricular Streptozotocin Injections as a Model of Alzheimer's Disease: in Search of a Relevant Mechanism. Molecular Neurobiology, 2016, 53, 1741-1752.	4.0	237
222	Antiâ€diabetic and neuroprotective effects of pancreatic islet transplantation into the central nervous system. Diabetes/Metabolism Research and Reviews, 2016, 32, 11-20.	4.0	10
223	Insulin and the Brain. Journal of Intensive Care Medicine, 2017, 32, 48-58.	2.8	22
224	Cognitive impairment is correlated with insulin resistance degree: the "PA-NICO-study― Metabolic Brain Disease, 2017, 32, 799-810.	2.9	12
225	Edaravone attenuates intracerebroventricular streptozotocinâ€induced cognitive impairment in rats. European Journal of Neuroscience, 2017, 45, 987-997.	2.6	20

#	Article	IF	CITATIONS
226	Neurocognitive impairment in patients with comorbid diabetes mellitus and depression. Personalized Medicine in Psychiatry, 2017, 1-2, 2-10.	0.1	2
227	Treadmill Exercise Exerts Neuroprotection and Regulates Microglial Polarization and Oxidative Stress in a Streptozotocin-Induced Rat Model of Sporadic Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 56, 1469-1484.	2.6	150
228	Altered temporal lobe white matter lipid ion profiles in an experimental model of sporadic Alzheimer's disease. Molecular and Cellular Neurosciences, 2017, 82, 23-34.	2.2	11
229	Insulin deficiency results in reversible protein kinase A activation and tau phosphorylation. Neurobiology of Disease, 2017, 103, 163-173.	4.4	26
230	Chronic nicotine attenuates behavioral and synaptic plasticity impairments in a streptozotocin model of Alzheimer's disease. Neuroscience, 2017, 353, 87-97.	2.3	24
231	N-acetylcysteine treatment attenuates the cognitive impairment and synaptic plasticity loss induced by streptozotocin. Chemico-Biological Interactions, 2017, 272, 37-46.	4.0	16
232	Rat brain glucose transporter-2, insulin receptor and glial expression are acute targets of intracerebroventricular streptozotocin: risk factors for sporadic Alzheimer's disease?. Journal of Neural Transmission, 2017, 124, 695-708.	2.8	39
233	Streptozotocin alters glucose transport, connexin expression and endoplasmic reticulum functions in neurons and astrocytes. Neuroscience, 2017, 356, 151-166.	2.3	20
234	Neuroprotective role of GABAB receptor modulation against streptozotocin-induced behavioral and biochemical abnormalities in rats. Neuroscience, 2017, 357, 67-74.	2.3	9
235	Diabetes and Alzheimer's Disease: Can Tea Phytochemicals Play a Role in Prevention?. Journal of Alzheimer's Disease, 2017, 59, 481-501.	2.6	46
236	Effect of Metformin on Adult Hippocampal Neurogenesis: Comparison with Donepezil and Links to Cognition. Journal of Molecular Neuroscience, 2017, 62, 88-98.	2.3	48
237	Long-term treatment with intranasal insulin ameliorates cognitive impairment, tau hyperphosphorylation, and microglial activation in a streptozotocin-induced Alzheimer's rat model. Scientific Reports, 2017, 7, 45971.	3.3	87
238	Glucose tolerance and insulin sensitivity are impaired in APP/PS1 transgenic mice prior to amyloid plaque pathogenesis and cognitive decline. Experimental Gerontology, 2017, 88, 9-18.	2.8	66
239	Methylene blue improves streptozotocin-induced memory deficit by restoring mitochondrial function in rats. Brain Research, 2017, 1657, 208-214.	2.2	22
240	mTORC2 (Rictor) in Alzheimer's Disease and Reversal of Amyloid-β Expression-Induced Insulin Resistance and Toxicity in Rat Primary Cortical Neurons. Journal of Alzheimer's Disease, 2017, 56, 1015-1036.	2.6	31
241	The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer's disease. Diabetes Research and Clinical Practice, 2017, 123, 192-198.	2.8	125
242	Obesity and Brain Function. Advances in Neurobiology, 2017, , .	1.8	3
243	Diabesity and Brain Energy Metabolism: The Case of Alzheimer's Disease. Advances in Neurobiology, 2017, 19, 117-150.	1.8	16

ARTICLE IF CITATIONS # Streptozotocin-induced hippocampal astrogliosis and insulin signaling malfunction as experimental 4.3 31 244 scales for subclinical sporadic Alzheimer model. Life Sciences, 2017, 188, 172-185. The diabetic brain and cognition. Journal of Neural Transmission, 2017, 124, 1431-1454. 245 2.8 Alzheimer's disease and metabolic syndrome: A link from oxidative stress and inflammation to 246 1.2 131 neurodegeneration. Synapse, 2017, 71, e21990. Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal. Biochimica Et Biophysica Acta - Molecular 247 393 Basis of Disease, 2017, 1863, 1078-1089. Pterostilbene ameliorates intracerebroventricular streptozotocin induced memory decline in rats. 248 4.0 27 Cognitive Neurodynamics, 2017, 11, 35-49. Intranasal Insulin Administration Ameliorates Streptozotocin (ICV)-Induced Insulin Receptor Dysfunction, Neuroinflammation, Amyloidogenesis, and Memory Impairment in Rats. Molecular 4.0 Neurobiology, 2017, 54, 6507-6522. Diabetes Mellitus and Alzheimer's Disease: The Protection of Epigallocatechin-3-gallate in 250 3.5 22 Streptozotocin Injection-Induced Models. Frontiers in Pharmacology, 2017, 8, 834. The role of melatonin in the onset and progression of type 3 diabetes. Molecular Brain, 2017, 10, 35. 2.6 14 The Importance of Olfactory and Motor Endpoints for Zebrafish Models of Neurodegenerative 252 1 Disease., 2017, , 525-554. Taraxerol as a possible therapeutic agent on memory impairments and Alzheimer's disease: Effects 254 1.8 against scopolamine and streptozotocin-induced cognitive dysfunctions. Steroids, 2018, 132, 5-11. Impaired insulin signaling and spatial learning in middle-aged rats: The role of PTP1B. Experimental 255 2.8 20 Gerontology, 2018, 104, 66-71. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's 4.1 126 disease models. Neuropharmacology, 2018, 136, 251-259. Thermoregulatory profile of neurodegenerationâ€induced dementia of the Alzheimer's type using 257 3.8 8 intracerebroventricular streptozotocin in rats. Acta Physiologica, 2018, 224, e13084. Targeting Insulin for Alzheimer's Disease: Mechanisms, Status and Potential Directions. Journal of Alzheimer's Disease, 2018, 64, S427-S453. 2.6 The 20-Year Voyage Aboard the Journal of Alzheimer's Disease: Docking at †Type 3 Diabetes', 259 Environmental/Exposure Factors, Pathogenic Mechanisms, and Potential Treatments. Journal of 2.6 48 Alzheimer's Disease, 2018, 62, 1381-1390. Effects of paeoniflorin on neurobehavior, oxidative stress, brain insulin signaling, and synaptic alterations in intracerebroventricular streptozotocin-induced cognitive impairment in mice. 46 Physiology and Behavior, 2018, 191, 12-20. A transient insulin system dysfunction in newborn rat brain followed by neonatal intracerebroventricular administration of streptozotocin could be accompanied by a labile cognitive 261 1.9 4 impairment. Neuroscience Research, 2018, 132, 17-25. Diabetes and Alzheimer's Disease., 2018, , 101-111.

#	Article	IF	CITATIONS
263	Shared pathological pathways of Alzheimer's disease with specific comorbidities: current perspectives and interventions. Journal of Neurochemistry, 2018, 144, 360-389.	3.9	10
264	Neuroprotective effects of tenuigenin on neurobehavior, oxidative stress, and tau hyperphosphorylation induced by intracerebroventricular streptozotocin in rats. Brain Circulation, 2018, 4, 24.	1.8	20
265	Moderating Effect of Insulin Resistance on the Relationship between Gray Matter Volumes and Cognitive Function. Journal of Clinical Medicine, 2018, 7, 413.	2.4	2
266	The Role of Long Noncoding RNAs in Diabetic Alzheimer's Disease. Journal of Clinical Medicine, 2018, 7, 461.	2.4	8
267	Two-dimensional ultraviolet spectroscopy of proteins. Science China Chemistry, 2018, 61, 1099-1109.	8.2	1
268	Effects of cinnamic acid on memory deficits and brain oxidative stress in streptozotocin-induced diabetic mice. Korean Journal of Physiology and Pharmacology, 2018, 22, 257.	1.2	47
269	The Early Events That Initiate β-Amyloid Aggregation in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 359.	3.4	85
270	Inflammation as a central mechanism in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 575-590.	3.7	1,254
271	Characterization of Impaired Cerebrovascular Structure in APP/PS1 Mouse Brains. Neuroscience, 2018, 385, 246-254.	2.3	40
272	Insulin-Like Growth Factor Binding Protein 2 Is Associated With Biomarkers of Alzheimer's Disease Pathology and Shows Differential Expression in Transgenic Mice. Frontiers in Neuroscience, 2018, 12, 476.	2.8	25
273	Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. Frontiers in Neuroscience, 2018, 12, 37.	2.8	132
274	Intracerebroventricular streptozotocinâ€induced Alzheimer's diseaseâ€like sleep disorders in rats: Role of the CABAergic system in the parabrachial complex. CNS Neuroscience and Therapeutics, 2018, 24, 1241-1252.	3.9	9
275	NO-Dependent Akt Inactivation by S-Nitrosylation as a Possible Mechanism of STZ-Induced Neuronal Insulin Resistance. Journal of Alzheimer's Disease, 2018, 65, 1427-1443.	2.6	9
276	Evaluation of neuropathological effects of a high-fat high-sucrose diet in middle-aged male C57BL6/J mice. Physiological Reports, 2018, 6, e13729.	1.7	22
277	Cortical tau burden and behavioural dysfunctions in mice exposed to monosodium glutamate in early life. PLoS ONE, 2019, 14, e0220720.	2.5	7
278	Hypothesis: Etiologic and Molecular Mechanistic Leads for Sporadic Neurodegenerative Diseases Based on Experience With Western Pacific ALS/PDC. Frontiers in Neurology, 2019, 10, 754.	2.4	29
279	The effects of insulin and insulin-like growth factor I on amyloid precursor protein phosphorylation in vitro and in vivo models of Alzheimer's disease. Neurobiology of Disease, 2019, 132, 104541.	4.4	38
280	Neurobehavioral investigation and acetylcholinesterase inhibitory activity study for some new coumarin derivatives. European Journal of Medicinal Chemistry, 2019, 182, 111651.	5.5	15

#	Article	IF	CITATIONS
281	Resveratrol and Metformin Recover Prefrontal Cortex AMPK Activation in Diet-Induced Obese Mice but Reduce BDNF and Synaptophysin Protein Content. Journal of Alzheimer's Disease, 2019, 71, 945-956.	2.6	23
282	Moderate protective effect of Kyotorphin against the late consequences of intracerebroventricular streptozotocin model of Alzheimer's disease. Amino Acids, 2019, 51, 1501-1513.	2.7	8
283	Altered expression of insulinâ€degrading enzyme and regulator of calcineurin in the rat intracerebral streptozotocin model and human apolipoprotein Eâ€îµ4–associated Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 392-404.	2.4	20
284	The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice. International Journal of Molecular Sciences, 2019, 20, 2539.	4.1	19
285	The Full Spectrum of Alzheimer's Disease Is Rooted in Metabolic Derangements That Drive Type 3 Diabetes. Advances in Experimental Medicine and Biology, 2019, 1128, 45-83.	1.6	39
286	The Role of Insulin-Like Growth Factors and Insulin-Like Growth Factor–Binding Proteins in the Nervous System. Biochemistry Insights, 2019, 12, 117862641984217.	3.3	103
287	Role of Mitochondria in Neurodegeneration in Obesity and Type 2 Diabetes. , 2019, , 301-322.		0
288	Crucial players in Alzheimer's disease and diabetes mellitus: Friends or foes?. Mechanisms of Ageing and Development, 2019, 181, 7-21.	4.6	27
289	Protection of cholinergic and antioxidant system contributes to the effect of Vitamin D <sub>3</sub> ameliorating memory dysfunction in sporadic dementia of Alzheimer's type. Redox Report, 2019, 24, 34-40.	4.5	10
290	Early-Stage Alzheimer's Disease Is Associated with Simultaneous Systemic and Central Nervous System Dysregulation of Insulin-Linked Metabolic Pathways. Journal of Alzheimer's Disease, 2019, 68, 657-668.	2.6	43
291	Current state of research on nonâ€human primate models of Alzheimer's disease. Animal Models and Experimental Medicine, 2019, 2, 227-238.	3.3	29
292	Cannabinoid Receptor Type 1 Agonist ACEA Improves Cognitive Deficit on STZ-Induced Neurotoxicity Through Apoptosis Pathway and NO Modulation. Neurotoxicity Research, 2019, 35, 516-529.	2.7	22
293	Impaired chemoreflex correlates with decreased c-Fos in respiratory brainstem centers of the streptozotocin-induced Alzheimer's disease rat model. Experimental Neurology, 2019, 311, 285-292.	4.1	9
294	MA-[d-Leu-4]-OB3, a Small Molecule Synthetic Peptide Leptin Mimetic, Mirrors the Cognitive Enhancing Action of Leptin in a Mouse Model of Type 1 Diabetes Mellitus and Alzheimer's Disease-Like Cognitive Impairment. International Journal of Peptide Research and Therapeutics, 2020, 26, 1243-1249.	1.9	5
295	GIP has neuroprotective effects in Alzheimer and Parkinson's disease models. Peptides, 2020, 125, 170184.	2.4	52
296	Prenatal stress promotes icv-STZ-induced sporadic Alzheimer's pathology through central insulin signaling change. Life Sciences, 2020, 241, 117154.	4.3	3
297	Critical Review of the Alzheimer's Disease Non-Transgenic Models: Can They Contribute to Disease Treatment?. Journal of Alzheimer's Disease, 2021, 82, S227-S250.	2.6	6
298	Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones. International Review of Neurobiology, 2020, 155, 37-64.	2.0	24

#	Article	IF	CITATIONS
299	Metformin loaded phosphatidylserine nanoliposomes improve memory deficit and reduce neuroinflammation in streptozotocin-induced Alzheimer's disease model. Life Sciences, 2020, 255, 117861.	4.3	55
300	Brain insulin resistance: role in neurodegenerative disease and potential for targeting. Expert Opinion on Investigational Drugs, 2020, 29, 333-348.	4.1	94
301	Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease. Journal of Neural Transmission, 2020, 127, 231-250.	2.8	13
302	Effect of amyloid toxicity or chronic cerebral hypoperfusion on brain insulin resistance in a rat model with intracerebroventricular streptozotocin. Brain Research Bulletin, 2020, 158, 40-50.	3.0	4
303	Meclizine ameliorates memory deficits in streptozotocin-induced experimental dementia in mice: role of nuclear pregnane X receptors. Canadian Journal of Physiology and Pharmacology, 2020, 98, 383-390.	1.4	6
304	Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review. Journal of Integrative Medicine, 2020, 18, 125-151.	3.1	31
305	Metabolic Stress Alters Antioxidant Systems, Suppresses the Adiponectin Receptor 1 and Induces Alzheimer's Like Pathology in Mice Brain. Cells, 2020, 9, 249.	4.1	21
306	The novel GLPâ€1/GIP analogue DA5â€CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD. Brain and Behavior, 2020, 10, e01505.	2.2	36
307	Synchronous nonmonotonic changes in functional connectivity and white matter integrity in a rat model of sporadic Alzheimer's disease. NeuroImage, 2021, 225, 117498.	4.2	14
308	Additional methodological considerations regarding optimization of the dose of intracerebroventricular streptozotocin A response to: "Optimization of intracerebroventricular streptozotocin dose for the induction of neuroinflammation and memory impairments in ratsâ€-by Chosh et al., Metab Brain Dis 2020 Iuly 21. Metabolic Brain Disease, 2021, 36, 97-102.	2.9	14
309	Does hearing loss lead to dementia? A review of the literature. Hearing Research, 2021, 402, 108038.	2.0	37
310	A Glycolysis Gene Methylation Prediction Model Based on Explainable Machine Learning for Alzheimer's Disease. SSRN Electronic Journal, 0, , .	0.4	0
311	Experimental Approach to Alzheimer's Disease with Emphasis on Insulin Resistance in the Brain. , 2021, , 1-52.		4
312	Suppression of neuronal cholesterol biosynthesis impairs brain functions through insulin-like growth factor I-Akt signaling. International Journal of Biological Sciences, 2021, 17, 3702-3716.	6.4	4
313	Expression of glucose transporters in human neurodegenerative diseases. Biochemical and Biophysical Research Communications, 2021, 540, 8-15.	2.1	21
314	Potential of Caffeine in Alzheimer's Disease—A Review of Experimental Studies. Nutrients, 2021, 13, 537.	4.1	44
315	PIRACY: An Optimized Pipeline for Functional Connectivity Analysis in the Rat Brain. Frontiers in Neuroscience, 2021, 15, 602170.	2.8	12
316	7,8-Dihydroxyflavone improves cognitive functions in ICV-STZ rat model of sporadic Alzheimer's disease by reversing oxidative stress, mitochondrial dysfunction, and insulin resistance. Psychopharmacology, 2021, 238, 1991-2009.	3.1	34

#	Article	IF	CITATIONS
317	Cardio- and Neurometabolic Adipobiology: Consequences and Implications for Therapy. International Journal of Molecular Sciences, 2021, 22, 4137.	4.1	12
318	Metformin: A Growing Journey from Glycemic Control to the Treatment of Alzheimer's Disease and Depression. Current Medicinal Chemistry, 2021, 28, 2328-2345.	2.4	15
319	Protective properties of GLPâ€1 and associated peptide hormones in neurodegenerative disorders. British Journal of Pharmacology, 2022, 179, 695-714.	5.4	55
320	Insulin Resistance as a Common Link Between Current Alzheimer's Disease Hypotheses. Journal of Alzheimer's Disease, 2021, 82, 71-105.	2.6	21
321	Research on the Glial–Lymphatic System and Its Relationship With Alzheimer's Disease. Frontiers in Neuroscience, 2021, 15, 605586.	2.8	5
322	Probiotics Fermentation Technology, a Novel Kefir Product, Ameliorates Cognitive Impairment in Streptozotocin-Induced Sporadic Alzheimer's Disease in Mice. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-18.	4.0	10
323	Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis. Current Drug Targets, 2022, 23, 311-327.	2.1	1
324	A Neonatal Mild Defect in Brain Insulin Signaling Predisposes a Subclinical Model of Sporadic Alzheimer's to Develop the Disease. Journal of Molecular Neuroscience, 2021, 71, 1473-1484.	2.3	3
325	Metabolic Syndrome as a Risk Factor for Alzheimer Disease. , 2013, , 281-341.		3
326	An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease–associated Al² oligomers. Journal of Clinical Investigation, 2012, 122, 1339-1353.	8.2	697
327	Cognitive dysfunctions in individuals with diabetes mellitus. Yeungnam University Journal of Medicine, 2019, 36, 183-191.	1.4	42
328	Therapeutic Advantages of Dual Targeting of PPAR-Î′ and PPAR-γ in an Experimental Model of Sporadic Alzheimer's Disease. Journal of Parkinson's Disease and Alzheimer's Disease, 2018, 5, 01-08.	0.8	12
329	Protective Effects of a Rhodiola Crenulata Extract and Salidroside on Hippocampal Neurogenesis against Streptozotocin-Induced Neural Injury in the Rat. PLoS ONE, 2012, 7, e29641.	2.5	111
330	Adipobiology of the brain: From brain diabetes to adipose Alzheimerââ,¬Ëœs disease. Adipobiology, 2016, 7, 37.	0.1	2
331	NGF-ome: its metabotrophic expression. Homage to Rita Levi-Montalcini. Biomedical Reviews, 2014, 21, 25.	0.6	1
332	Effects of Herbal Compound (IMOD) on Behavior and Expression of Alzheimer's Disease Related Genes in Streptozotocin-Rat Model of Sporadic Alzheimer's Disease. Advanced Pharmaceutical Bulletin, 2017, 7, 491-494.	1.4	7
333	Cervical Vagal Schwannoma Review of all Reported Cases and Our Reports. International Journal of Neurology and Brain Disorders, 2016, 3, 1-6.	0.0	5
334	Neuroprotective Effect of Garcinia Mangostana on Streptozotocin Induced Sporadic Type Alzheimer's Disease in Mice. International Journal of Applied Pharmaceutical Sciences and Research, 2016, 1, 8-15.	0.2	3

#	Article	IF	CITATIONS
335	Therapeutic Approaches to Alzheimer's Type of Dementia: A Focus on FGF21 Mediated Neuroprotection. Current Pharmaceutical Design, 2019, 25, 2555-2568.	1.9	25
336	Role of Gut Microbiota in Obesity, Type 2 Diabetes and Alzheimer's Disease. CNS and Neurological Disorders - Drug Targets, 2014, 13, 305-311.	1.4	94
337	Diabetes of the Brain: Computational Approaches and Interventional Strategies. CNS and Neurological Disorders - Drug Targets, 2014, 13, 408-417.	1.4	16
338	Extending Arms of Insulin Resistance from Diabetes to Alzheimer's Disease: Identification of Potential Therapeutic Targets. CNS and Neurological Disorders - Drug Targets, 2019, 18, 172-184.	1.4	14
339	Therapeutic targets of brain insulin resistance in sporadic Alzheimer s disease. Frontiers in Bioscience - Elite, 2012, E4, 1582-1605.	1.8	50
340	Dysregulation of Insulin-Linked Metabolic Pathways in Alzheimer's Disease: Co-Factor Role of Apolipoprotein E ɛ4. Journal of Alzheimer's Disease Reports, 2020, 4, 479-493.	2.2	7
341	The relationship between glucose excursion and cognitive function in aged type 2 diabetes patients. Biomedical and Environmental Sciences, 2012, 25, 1-7.	0.2	45
342	Myricetin protects hippocampal CA3 pyramidal neurons and improves learning and memory impairments in rats with Alzheimer's disease. Neural Regeneration Research, 2016, 11, 1976.	3.0	68
343	Mitochondrial protective and anti-apoptotic effects of Rhodiola crenulata extract on hippocampal neurons in a rat model of Alzheimer's disease. Neural Regeneration Research, 2017, 12, 2025.	3.0	17
344	Alteration in memory cognition due to activation of caveolin-1 and oxidative damage in a model of dementia of Alzheimer's type. Indian Journal of Pharmacology, 2019, 51, 173.	0.7	13
345	Insulin Resistance: A Bridge between T2DM and Alzheimer's Disease. Journal of Diabetes & Metabolism, 2013, 04, .	0.2	1
346	Sustained Impairments in Brain Insulin/Igf Signaling in Adolescent Rats Subjected to Binge Alcohol Exposure during Development. , 2012, 02, .		19
347	Efficacy of Adjunctive Extra Virgin Coconut Oil Use in Moderate to Severe Alzheimer?s Disease. International Journal of School and Cognitive Psychology, 2014, 1, .	0.2	2
348	Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal. World Journal of Diabetes, 2015, 6, 1223.	3.5	35
349	Insulin resistance and Alzheimer's disease. BMB Reports, 2009, 42, 475-481.	2.4	338
350	Neurotrophic and metabotrophic potential of nerve growth factor and brain-derived neurotrophic factor: Linking cardiometabolic and neuropsychiatric diseases. World Journal of Pharmacology, 2013, 2, 92.	2.3	40
351	Insulin Resistance, Cognitive Impairment and Neurodegeneration: Roles of Nitrosamine Exposure, Diet and Lifestyles. , 0, , .		3
352	Diabetes and dementia: a common link or coincidental coexistence?. Biomedical Reviews, 2014, 18, 59.	0.6	4

#	Article	IF	CITATIONS
353	Amyloid and Neurodegeneration: Alzheimer's Disease and Retinal Degeneration. , 2009, , 131-163.		1
354	The Role of Insulin Resistance in Age-Related Cognitive Decline and Dementia. , 2009, , 433-457.		Ο
355	Ceramide and Ceramide 1 Phosphate in the Brain. , 2011, , 217-243.		0
357	PPAR-δ Agonist Rescue of Brain Insulin/IGF Signaling Impairments Following Developmental Exposure to Alcohol. Journal of Drug and Alcohol Research, 2013, 2, 1-11.	0.9	0
358	Quasi-Particle Approach to 2D IR Spectra of Vibrational Excitons in Biomolecules: Molecular Dynamics versus Stochastic Simulation Protocols. , 2013, , 418-449.		0
360	Experimental Approach to Alzheimer Disease. , 2014, , 2025-2045.		Ο
362	Insulin Resistance and Oligodendrocyte/Microvascular Endothelial Cell Dysfunction as Mediators of White Matter Degeneration in Alzheimer's Disease. , 0, , 123-145.		0
363	Infection and Immunometabolism in the Central Nervous System: A Possible Mechanistic Link Between Metabolic Imbalance and Dementia. Frontiers in Cellular Neuroscience, 2021, 15, 765217.	3.7	17
364	Inflammation and insulin resistance in Alzheimer's disease. , 2020, , 389-405.		1
365	Intracerebroventricular streptozotocin induces behavioral impairments and increases short-term C3 gene expression in the hippocampus of Wistar rats. Acta Neurobiologiae Experimentalis, 2020, 80, 160-169.	0.7	1
367	Dor psicopatológica antes do desenvolvimento da doença de Alzheimer. Journal Health NPEPS, 2020, 5, 417-429.	0.2	0
368	POTENTIAL NON-GROWTH USES OF rhIGF-I. Growth, Genetics & Hormones, 2007, 23, 1-7.	0.0	2
369	Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease. Journal of Alzheimer's Disease, 2009, 17, 827-44.	2.6	92
371	Role of central nervous system insulin resistance in fetal alcohol spectrum disorders. Journal of Population Therapeutics and Clinical Pharmacology, 2010, 17, e390-404.	1.4	22
373	Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulin-resistance diseases. Panminerva Medica, 2012, 54, 171-8.	0.8	32
375	Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Current Opinion in Investigational Drugs, 2009, 10, 1049-60.	2.3	99
376	Gallium Nanoparticle-Mediated Reduction of Brain Specific Serine Protease-4 in an Experimental Metastatic Cancer Model. Asian Pacific Journal of Cancer Prevention, 2017, 18, 895-903.	1.2	4
377	Differential Effects of 3rd Trimester-Equivalent Binge Ethanol and Tobacco-Specific Nitrosamine Ketone Exposures on Brain Insulin Signaling in Adolescence. , 2016, 1, .		3

#	Article	IF	CITATIONS
379	Astrocytes as Key Regulators of Brain Energy Metabolism: New Therapeutic Perspectives. Frontiers in Physiology, 2021, 12, 825816.	2.8	76
380	A PDK-1 allosteric agonist neutralizes insulin signaling derangements and beta-amyloid toxicity in neuronal cells and in vitro. PLoS ONE, 2022, 17, e0261696.	2.5	3
381	Effect of curcumin nanoparticles on streptozotocin-induced male Wistar rat model of Alzheimer's disease. Metabolic Brain Disease, 2022, 37, 343-357.	2.9	17
382	Shared Molecular Mechanisms among Alzheimer's Disease, Neurovascular Unit Dysfunction and Vascular Risk Factors: A Narrative Review. Biomedicines, 2022, 10, 439.	3.2	8
383	A Bioinformatics Approach Toward Unravelling the Synaptic Molecular Crosstalk Between Alzheimer's Disease and Diabetes. Journal of Alzheimer's Disease, 2022, , 1-17.	2.6	3
384	A Genetic Model of Epilepsy with a Partial Alzheimer's Disease-Like Phenotype and Central Insulin Resistance. Molecular Neurobiology, 2022, 59, 3721-3737.	4.0	5
390	Amelioration of intracerebroventricular streptozotocin-induced cognitive dysfunction by Ocimum sanctum L. through the modulation of inflammation and GLP-1 levels. Metabolic Brain Disease, 0, , .	2.9	3
391	Relationship between Brain Metabolic Disorders and Cognitive Impairment: LDL Receptor Defect. International Journal of Molecular Sciences, 2022, 23, 8384.	4.1	12
392	The effect of chronic stress and its preconditioning on spatial memory as well as hippocampal LRP1 and RAGE expression in a streptozotocin-induced rat model of Alzheimer's disease. Metabolic Brain Disease, 2022, 37, 2699-2710.	2.9	1
393	Animal model of Alzheimer's disease induced by streptozotocin: New insights about cholinergic pathway. Brain Research, 2023, 1799, 148175.	2.2	8
394	High-Intense Interval Training Prevents Cognitive Impairment And Increases The Expression Of Muscle Genes Fndc5 And Ppargc1a In A Rat Model Of Alzheimer's Disease. Current Alzheimer Research, 2022, 20,	1.4	0
395	Type 2 Diabetes Mellitus and Alzheimer's Disease: Shared Molecular Mechanisms and Potential Common Therapeutic Targets. International Journal of Molecular Sciences, 2022, 23, 15287.	4.1	26
396	Streptozotocin mechanisms and its role in rodent models for Alzheimer's disease. Toxin Reviews, 2023, 42, 491-502.	3.4	3
397	Experimental Approach to Alzheimer's Disease with Emphasis on Insulin Resistance in the Brain. , 2022, , 1657-1708.		0
398	Effect of Memantine on Expression of NAT-Rad18, Rad18 and Sorl1 Genes in Rat Model of Alzheimer's Disease. Majallah-i 'ilmi Pizhuhishi-i Danishgah-i 'Ulum-i Pizishki Va Khadamat-i Bihdashti-i Darmani-i Zanjan, 2023, 31, 86-92.	0.1	0
399	The sodium glucose co-transporter 2 inhibitor ertugliflozin for Alzheimer's disease: Inhibition of brain insulin signaling disruption-induced tau hyperphosphorylation. Physiology and Behavior, 2023, 263, 114134.	2.1	0
400	Relationship between glycemic control and cognitive impairment: A systematic review and meta-analysis. Frontiers in Aging Neuroscience, 0, 15, .	3.4	8
402	Audiogenic Seizures in the Streptozotocin-Induced Rat Alzheimer's Disease Model. Journal of Alzheimer's Disease, 2023, 94, 1179-1196.	2.6	0

ARTICLE IF CITATIONS Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer's disease models: a 404 3.5 4 systematic review and meta-analysis of preclinical studies. Frontiers in Pharmacology, 0, 14, . Evidence of disturbed insulin signaling in animal models of Alzheimer's disease. Neuroscience and 6.1 Biobehavioral Reviews, 2023, 152, 105326. Tau Loss of Function, by Deletion or Aggregation, Contributes to Peripheral Insulin Resistance. 406 2.6 0 Journal of Alzheimer's Disease, 2023, 95, 1041-1058. Malignant Brain Aging: The Formidable Link Between Dysregulated Signaling Through Mechanistic Target of Rapamycin Pathways and Alzheimer's Disease (Type 3 Diabetes). Journal of Alzheimer's Disease, 2023, 95, 1301-1337. Protective Effects of Repetitive Transcranial Magnetic Stimulation Against Streptozotocin-Induced 408 4.0 1 Alzheimer's Disease. Molecular Neurobiology, 2024, 61, 1687-1703. Subject classification and cross-time prediction based on functional connectivity and white matter microstructure features in a rat model of Alzheimer's using machine learning. Alzheimer's Research 409 6.2 and Therapy, 2023, 15, . Exendin-4 Prevents Memory Loss and Neuronal Death in Rats with Sporadic Alzheimer-Like Disease. 410 4.0 1 Molecular Neurobiology, 0, , . Alzheimer's disease, a metabolic disorder: Clinical advances and basic model studies (Review). 1.8 Experimental and Therapeutic Medicine, 2023, 27, . 412 Monitoring Alzheimer's disease via ultraweak photon emission. IScience, 2024, 27, 108744. 4.1 0 The effect of intra-nasal co-treatment with insulin and growth factor-rich serum on behavioral defects, hippocampal oxidative-nitrosative stress, and histological changes induced by icv-STZ in a rat model. Naunyn-Schmiedeberg's Archives of Pharmacology, 0, , . Agent Orange Herbicidal Toxin-Initiation of Alzheimer-Type Neurodegeneration. Journal of Alzheimer's 414 0 2.6 Disease, 2024, 97, 1703-1726. Improvement of Learning and Memory by Chickpeas (Cicer arietinum L.) Sprout Against Streptozotocin 0.3 and Induced Amnesia in Rats. International Journal of Pharmacology, 2024, 20, 22-33.